FIELD: medicine. SUBSTANCE: method involves administering phase-specific cytotoxic preparations periodically in multiple series. The period is selected to provide resonance maximum survival rate of the critical biological tissue from the point of view of agent applied. EFFECT: enhanced effectiveness of treatment.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SELECTING MEDICINAL PREPARATIONS POSSESSING ANTICANCEROGENIC ACTIVITY | 1994 |
|
RU2046340C1 |
| METHOD OF SELECTING MEDICINAL PREPARATION POSSESSING ANTICANCEROGENIC ACTIVITY | 1994 |
|
RU2046341C1 |
| PEPTIDE, POSSESSING ANTI-TUMOR AND ANTI-METASTATIC ACTIVITY, AND FINISHED DOSAGE FORM BASED THEREON | 2018 |
|
RU2682039C1 |
| METHOD OF THERAPY OF MALIGNANT DISEASES | 2013 |
|
RU2597414C2 |
| PHARMACOLOGICAL COMBINATION OF POLYCATIONIC CARRIER PEG-PEI-TAT WITH INCLUDED IN IT PLASMID CARRYING THERAPEUTIC GENES HSVtk AND GM-CSF FOR GENE THERAPY OF TUMOROUS DISEASES | 2013 |
|
RU2575077C2 |
| SPECIFIC COMBINED THERAPY OF MALIGNANT TUMOURS WITH CYTOSTATIC AGENT AND ITS MODIFYING AGENT | 2015 |
|
RU2571551C1 |
| METHOD OF TREATING MALIGNANCIES IN MAMMALS | 2011 |
|
RU2461566C1 |
| METHOD OF SUPPRESSING GROWTH OF TUMOURS WITH GENETICALLY MODIFIED VERSION OF TRAIL CYTOKINE | 2019 |
|
RU2727059C1 |
| PHARMACEUTICAL COMPOSITION ELICITING ANTITUMOR EFFECT WITH REDUCED ADVERSE EFFECTS AND CONTAINING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2214238C2 |
| POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 |
|
RU2595859C1 |
